Physician

Abdul Sorathia, MD

According to 2025 Medicare claims, Abdul Sorathia, MD (NPI: 1336241413) practices medical oncology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is HALIFAX HEALTHCARE SYSTEMS INC (NPI: 1245283530; TIN: 592898487) and primary practice location at 32114-2709.

Sorathia's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 203 traditional Medicare patients, billed 739 HCPCS/CPT codes, and received $71,678 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 981 prescription claims across 205 beneficiaries totaling $2,563,024 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2023 DME data shows 11 claims. Open Payments data shows 18 records totaling $4,595. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $94,077 to $71,678. Concurrently, Part D prescription costs have changed little. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	444	1,689	$94,077
2016	425	1,768	$117,469
2017	459	1,816	$109,754
2018	432	1,475	$105,846
2019	395	1,270	$89,740
2020	383	1,163	$79,930
2021	390	1,189	$101,078
2022	326	934	$74,693
2023	286	878	$79,569
2024	203	739	$71,678

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	242	1,302	$1,564,521
2016	239	1,239	$1,593,477
2017	326	1,538	$1,920,689
2018	312	1,413	$2,164,521
2019	294	1,284	$2,088,842
2020	301	1,340	$2,381,443
2021	288	1,201	$2,403,063
2022	240	1,070	$2,204,196
2023	214	978	$2,088,183
2024	205	981	$2,563,024

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	90	$7,541
2016	N/R	32	$1,119
2017	N/R	N/R	N/R
2018	N/R	12	$2,855
2019	N/R	37	$2,716
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	11	$207
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	43	43	$137
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	25	28	$135
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	127	365	$106
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	26	96	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	127	201	$70

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	43	1,290	$608,896
Calquence	Acalabrutinib Maleate	29	870	$382,684
Xtandi	Enzalutamide	19	570	$263,028
Lenalidomide	Lenalidomide	21	588	$257,389
Lenvima	Lenvatinib Mesylate	11	330	$242,372

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	18	$4,595	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdul Sorathia, MD?

Tedicare shows public-source Medicare data for Abdul Sorathia, MD (NPI 1336241413), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdul Sorathia, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Abdul Sorathia, MD?

Abdul Sorathia, MD is linked to HALIFAX HEALTHCARE SYSTEMS INC (billing NPI 1245283530) in the available physician profile data.

Does Abdul Sorathia, MD have Open Payments data?

Abdul Sorathia, MD has 18 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.